Validation of the new diagnostic complex of biomarkers for differential diagnosis of Alzheimer’s disease
For studies were selected 147 patients with verified diagnosis of Alzheimer’s disease (n=17), early form of Alzheimer’s disease (n=30) and chronic ischemia with vascular dementia (n=100). Established the high efficiency of diagnostic complex of biomarkers, including a definition degidroepiandrosteron sulfate (DHEA-S), apolipoprotein E4 (Apo-E4) and the amyloid beta protein (Aβ1-42), for the early diagnosis and to identify risk groups of Alzheimer’s disease: increase in markers of Aβ1-42 and Apo-E4 at patients within the 25-50% and decreased DHEA-S on 40-50% indicated the development in a patient the chronic cerebral ischemia; increasing the concentration of markers Aβ1-42 and Apo-E4 at patients within 50-100% and decrease DHEA-S more than 10 times established the early forms of AD; in developed AD the markers of Aβ1-42 and Apo-E4 increased many times and a decrease DHEA-S with more than 10 times.